



Clinical Commissioning Policy Proposition: Second allogeneic haematopoietic stem cell transplant for relapsed disease

Reference: NHS England F01X07/01

First published: March 2016

**Prepared by NHS England Specialised Services Clinical Reference Group for
Blood & Marrow Transplantation**

Published by NHS England, in electronic format only.

Contents

Contents	3
1 Executive Summary	4
Equality Statement.....	4
Plain Language Summary.....	4
2 Introduction	5
3 Proposed Intervention and Clinical Indication	5
4 Definitions	6
5 Aims and Objectives	6
6 Epidemiology and Needs Assessment.....	7
7 Evidence Base	7
8 Proposed Criteria for Commissioning.....	9
9 Proposed Patient Pathway.....	9
10 Proposed Governance Arrangements.....	10
11 Proposed Mechanism for Funding	10
12 Proposed Audit Requirements	10
13 Documents That Have Informed This Policy Proposition	11
14 Date of Review.....	11

1 Executive Summary

Equality Statement

NHS England has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012. NHS England is committed to fulfilling this duty as to equality of access and to avoiding unlawful discrimination on the grounds of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, gender or sexual orientation. In carrying out its functions, NHS England will have due regard to the different needs of protected equality groups, in line with the Equality Act 2010. This document is compliant with the NHS Constitution and the Human Rights Act 1998. This applies to all activities for which NHS England is responsible, including policy development, review and implementation.

Plain Language Summary

The policy proposition aims to confirm NHS England's commissioning approach to second allogeneic haematopoietic stem cell transplantation in patients with relapsed disease.

Haematopoietic stem cell transplantation (HSCT) is also known as blood and marrow transplantation (BMT). Relapsed disease occurs when the signs and symptoms of a disease return after a period of remission.

Allogeneic HSCT is used to treat carefully selected patients with a range of malignant and non-malignant blood-related disorders and other specific disorders of the immune system. It involves replacing the bone marrow stem cells of a patient following high-dose therapy with stem cells from a tissue-type matched or mismatched donor.

NHS England has concluded that there is sufficient evidence to support a proposal for the routine commissioning of second allogeneic HSCTs for a small number of highly selected patients with relapsed disease.

2 Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to routinely commission second allogeneic HSCT transplant for a small number of highly selected patients with relapsed disease. Whilst the clinical evidence is limited and of poor quality, it is recognised that the low number of patients who might be suitable for this procedure – across a broad range of indications – means that high quality level 1 evidence is unlikely to become available to support the commissioning position.

This document also describes the proposed criteria for commissioning, proposed governance arrangements and proposed funding mechanisms.

For the purpose of consultation NHS England invites views on the evidence and other information that has been taken into account as described in this policy proposition.

A final decision as to whether second allogeneic HSCT transplant for a small number of highly selected patients with relapsed disease will be routinely commissioned is planned to be made by NHS England by June 2016 following a recommendation from the Clinical Priorities Advisory Group.

3 Proposed Intervention and Clinical Indication

Allogeneic haematopoietic stem cell transplant (Allo-HSCT) is used in the management of haematological malignancy to generate an anti-tumour immune response by replacing host bone marrow and immune system, usually after high dose of chemotherapy or radiotherapy. Allo-HSCT relies on a donor, and the donor and recipient are usually suitably matched for Major Histocompatibility Complex antigens (MHC), routinely tested on white blood cells. Closer matches are generally possible when a sibling donor is available. Alternatively, a suitably matched unrelated donor may be used, and alternative donor sources, such as mismatch unrelated and haplo-identical family donors, may be used in the absence of a fully matched donor. Stem cells are derived from bone marrow, peripheral blood and umbilical cord.

Although Allo-HSCT may be potentially curative in a range of haematological malignancies, disease relapse after a first transplant remains a significant problem and is the major cause of post-transplant mortality in some conditions e.g. myelodysplasia. The prognosis for patients with any haematological malignancy relapsing after an initial Allo-HSCT is poor, though the timeframe in which they relapse considerably alters their prognosis (<3 months vs 3-12 months vs >12

months following Allo-HSCT). The best therapeutic option for patients that relapse after their first Allo-HSCT is uncertain. Options include: further chemotherapy; withdrawal of immunosuppressive treatment (given to reduce graft-versus-host disease) in order to enable a graft-versus-leukaemia response; infusion of donor lymphocytes; treatment with cytokines; or a second Allo-HSCT.

4 Definitions

Allogeneic haemopoietic stem cell transplantation (Allo-HSCT) is used to treat carefully selected patients with a range of malignant and non-malignant haematological disorders and other specific disorders of the immune system. It involves replacing the bone marrow stem cells of a patient following high-dose therapy, with stem cells from a tissue-type matched or mismatched donor.

Relapsed disease is a recurrence of the disease.

Haematological malignancies are tumours that affect the blood, bone marrow, lymph, and lymphatic system.

Major Histocompatibility Complex antigens (MHC) is a group of genes that help the immune system recognise foreign substances. They stimulate an organism's immunological response to transplanted organs and tissues and are originally defined as the most important molecule involved in the rejection of these.

Graft-versus-host disease is a common complication following an Allogeneic tissue transplant where white blood cells (immune cells) in the tissue (the graft) recognise the recipient host as "foreign". The transplanted white blood cells then attack the host's body cells.

Graft-versus-leukaemia response is the desired effect following Allo-HSCT where donor cells eliminate malignant cells.

5 Aims and Objectives

The policy document aims to specify the clinical indications and their subgroups for which second allogeneic haematopoietic stem cell transplants will be commissioned routinely by NHS England.

The objective is to:

1. Ensure that repeat allogeneic HSCT is appropriately commissioned in line with the current (limited) evidence base
2. Reduce variation in access to repeat allogeneic HSCT
3. Promote the cost-effective use of resources

6 Epidemiology and Needs Assessment

HSCT offers a potential long-term curative option for a range of haematological malignancies but is associated with high treatment related mortality. Repeat transplant may be considered for primary graft failure/failure of engraftment as well as for treatment of relapse of the underlying disease. Relapse is the major cause of mortality in patients who have had an initially successful transplant. Post-transplant relapse rates vary by underlying condition and by clinical state at first transplantation (for example, whether the transplant was done in first or second remission; whether or not complete remission had been achieved at the time of transplantation, etc.).

The five-year incidence of relapse in low- and intermediate-risk leukaemias undergoing first Allo-HSCT in one US centre was reported as 32% (Carlens et al., 1998). For acute lymphoblastic leukaemia, a five -year relapse rate of 29% (+/- 9%) has been reported for patients transplanted whilst in first remission; and a rate of 52% (+/-8%) for patients transplanted in second remission (Barrett et al., 1989).

Data from NHS England suggests, over a 10 calendar year period (2000-2009, inclusive), 184 patients underwent a second Allo-HSCT for relapsed disease, primarily for acute myeloid leukaemia (AML 51%, CML 14%, lymphoma 7%, myeloma 2% & MDS 25%). Across the period the proportion of patients receiving a second Allo-HSCT where time from start of therapy to occurrence of 1st relapse (PFS1)>12 months was 67% with year-on-year trends.

7 Evidence Base

NHS England has concluded that there is sufficient evidence to support a proposal for the routine commissioning of second Allogeneic HSCT transplant for a small number of highly selected patients with relapsed disease. Whilst the clinical evidence is limited and of poor quality, it is recognised that the low number of patients who might be suitable for this procedure – across a broad range of indications – means that high quality level 1 evidence is unlikely to become available to support the commissioning position.

Whilst the evidence review focused on adults, second Allogeneic HSCT transplants for relapsed disease are a relevant treatment option for children. Data from the British Society for Blood and Marrow Transplantation (BSBMT) demonstrates that outcomes following HSCT are generally superior in children to those in adults across all indications. On this basis, extrapolating from the evidence for second transplant for relapse disease in adults, this policy proposition recommends access to patients of all ages meeting the commissioning criteria.

EVIDENCE REVIEW SUMMARY

1. Is allogeneic haematopoietic stem cell transplant clinically effective in the treatment of adult patients with haematological malignancy who have relapsed following an initial allogeneic transplant?

Published evidence of clinical effectiveness is limited to retrospective case series and two controlled studies. These are mostly single centre and report outcomes on patients treated over periods of more than twenty years, during which time approaches to treatment and options available may have varied. Risks of bias and confounding are inherent in the study design. The patients reported in these studies are heterogeneous with respect to disease, disease stage, previous treatment, conditioning regimes as well as demographic factors (age, gender, etc). The outcomes reported from these studies indicate a 5-year overall survival from allo-HSCT as a second transplant of 16% to 28%. Non-relapse mortality was reported as 18 to 63% over periods varying from 100 days to 5 years.

2. Is allogeneic haematopoietic stem cell transplant cost effective in the treatment of adult patients with haematological malignancy who have relapsed following an initial allogeneic transplant?

We found a study indicating the cost of second HSCTs at a hospital in the United States, but it did not report the cost effectiveness of the procedure.

3. Is there any evidence to indicate the comparative effectiveness of allo-HSCT compared to other management strategies in adult patients who have relapsed following an initial allogeneic transplant?

We found one study of the comparative effectiveness of allo-HSCT compared to other management strategies in patients who have relapsed following an initial transplant for haematological malignancy. It reported no significant difference in one-year survival rates between people with acute myeloid leukaemia and myelodysplastic syndrome treated with supportive care, palliative or intensive chemotherapy, a second allo-HSCT or other treatments. The only factor influencing overall survival was time to relapse after first allo-HSCT.

4. Is it possible to specify selection criteria which would enable the identification of those patients relapsing after an initial transplant who are most likely to have a favourable outcome from an allo-HSCT?

Univariate regression analysis in four studies suggested that longer time interval between first transplant and relapse (>1 year vs <1 year) is associated with better survival. One study also suggested that younger age (<40 years vs >40 years) at time of 2nd transplant and disease stage at second transplant (early versus advanced) may also be associated with better survival. Another study reported that longer survival was associated with longer duration of remission after first allo-HSCT, with lower stage at second HSCT and with a related first HSCT. A further study reported better outcomes in patients in remission at second transplant, with an interval from first transplant to relapse of more than ten months and those who received total body irradiation.

SUPPLEMENTARY EVIDENCE

A retrospective cohort study of 116 patients with acute myeloid leukaemia (AML), myelodysplastic syndromes and myeloproliferative disorders who underwent a second allo HSCT for disease relapse was accepted for publication in a peer reviewed journal in December 2015. (Orti G., et al.). At the time of second

transplant 80 patients (70%) had active disease, and 28 (25%) were in complete remission. Overall 5 year survival was 32% (SE 4.7%). In multivariable regression 3 factors were adversely associated with outcome survival: active disease at time of second transplant, time from first to second transplant less than 430 days, and donor other than an HLA matched sibling. Disease-free survival at 5 years was 30%, and 5 year non-relapse mortality was 32%. 47% of patients developed acute graft versus host disease (GvHD) and 32% developed chronic GvHD.

COMPARISON OF OVERALL SURVIVAL BETWEEN FIRST AND SECOND TRANSPLANT

Data from the British Society for Blood and Marrow Transplantation (BSBMT) database for the period 2007-2012, published in its report to commissioners (BSBMT 6th Report to Specialist Commissioners), were reviewed. These showed that: survival outcomes for allogeneic transplants using matched unrelated donors are nearly as good as those using sibling donors; five year overall survival of 30% is comparable with the outcomes of first transplant for some subgroups of acute leukaemia.

8 Proposed Criteria for Commissioning

Indications and contra-indications

Patients whose first allogeneic haematopoietic stem cell transplant (Allo-HSCT) results in relapse should be offered a second treatment, where:

- (i) Patient is in complete remission
- (ii) Patient relapses >12 months after first Allo-HSCT
- (iii) Patient is clinically fit to undergo treatment (as determined by MDT - see governance for more detail)

Exclusions

Patients whose first Allo-HSCT results in relapse should not be offered a second treatment, where:

- (i) Patient whose relapse occurs <12 months after first Allo-HSCT

No patients should be offered a further Allo-HSCT if their second results in relapse.

9 Proposed Patient Pathway

When patients relapse following their first Allo-HSCT, a multi-disciplinary team consisting of a haematology specialist, specialist nurse and transplant physicians is called to assess what clinical options are available. These include: further chemotherapy; withdrawal of immunosuppressive treatment (given to reduce graft-

versus-host disease); infusion of donor lymphocytes; treatment with cytokines; or a second Allo-HSCT. Where relapse has occurred >12 months after procedure, decision whether patient is clinically fit to undergo a second Allo-HSCT is taken. Due to the severity of the procedure, the wishes of the patient is taken into consideration on a case-by-case basis.

Where a decision to go ahead with a second Allo-HSCT is taken, the procedure is similar to that of the first. The transplant procedure begins with 'conditioning' therapy (chemotherapy with or without total body irradiation [TBI]) at a range of doses depending on the type and severity of disease being treated. The aim of conditioning is to:

1. Eradicate the host immune response, to minimise graft rejection
2. Kill leukaemia/tumour cells (in malignant diseases)
3. Eradicate existing bone marrow tissue (in order to provide space for engraftment of transplanted donor stem cells)

The patient pathway is described in detail in the BMT service specifications for adults.

10 Proposed Governance Arrangements

The governance arrangements are described in detail in the BMT service specifications for adults. All providers of HSCT must have JACIE accreditation.

Decision on patient treatment to be undertaken by Multi-Disciplinary Team consisting of haematology specialist, specialist nurse and transplant physicians.

Bone marrow, peripheral blood stem cells, or umbilical cord blood stem cells may be used as donor stem cell sources. Use of umbilical cord cells must be in line with the UK Cord Blood Working Group Recommendations for donor selection. Use of double cord units must be notified in advance to the commissioner in view of the likely increased costs and to ensure the selection protocol has been followed.

11 Proposed Mechanism for Funding

Treatment to be funded by NHS England.

12 Proposed Audit Requirements

Complete data must be submitted to the BSBMT registry for all transplants carried out by UK centres. This will enable better evaluation of clinical outcomes broken down by patient and disease-related variables. All centres must undergo regular JACIE inspection. All centres must provide the data required for the BMT Quality Dashboard. Audit requirements are described in more detail in the BMT service

specification.

Outcome data for second allogeneic transplants for relapsed disease must be separately identifiable within the BSBMT database, and specifically included within the annual BSBMT report to commissioners.

13 Documents That Have Informed This Policy Proposition

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised (January 2015). Reference: NHS England B04/P/a

BMT Service Specifications for adults, B04/S/a.

14 Date of Review

This document will lapse upon publication by NHS England of a clinical commissioning policy for the proposed intervention that confirms whether it is routinely or non-routinely commissioned (expected by June 2016)

END